Intraperitoneal Paclitaxel With XELOX in Gastric Cancer With Peritoneal Metastasis

1. Inclusion Criteria: * ECOG(Eastern Cooperative Oncology Group) performance status 0 or 1 * pathologically proven primary gastric adenocarcinoma * peritoneal metastasis confirmed by laparoscopy or diagnostic imaging * written informed consent * adequate function of important organs (within 14 days before registration) Absolute neutrophil count ≥1.5 x 10\^9/L, Platelet \>=100,000/mm3, Hemoglobin \>=8.0g/dL, Total bilirubin \<= ≤ 2.0mg/dl or ULN(Upper Limit of Normal) x 1.5, AST(aspartate aminotransferase) \<=100IU/L(International Unit/Liter), ALT(alanine transaminase) \<=100IU/L, Creatinine clearance ≥ 50mL/min (milliliter/minute), 2. Exclusion Criteria: * other active concomitant malignancies * HER2(human epidermal growth factor receptor 2) positive (Immunohistochemistry 3+ or 2+ with in situ hybridization positive) * no investigational anticancer therapy within 30 days prior to the first dose of study treatment * recent (within 6 months) acute coronary syndrome, severe heart failure or severe pulmonary disease * uncontrolled acute or chronic disease * uncontrolled infection or inflammation * uncontrolled psychiatric disorder or central neurologic disease * not fully recovered from previous surgery * prior anticancer therapy (chemotherapy, immunotherapy, radiation) within 6 months * intolerable to oral administration or a lack of physical integration of the upper gastrointestinal tract or with a malabsorption syndrome * fertile males and females who are unwilling to use effective contraceptive methods. * pregnancy, breast feeding or intention to become pregnant * interstitial pneumonia or pulmonary fibrosis * peripheral neuropathy with functional impairment * hypersensitivity to paclitaxel, oxaliplatin, capecitabine, fluoropyrimidine or Cremophor EL. * concomitant therapy with any substrate or inhibitor of Cytochrome P450 2C8 or 3A4 * concomitant therapy with sorivudine or brivudine * Dihydropyrimidine dehydrogenase (DPD) deficiency. * current or recent (within the 7 days prior to enrollment) treatment of tegafur-gimeracil-oteracil potassium